

Oral immunotherapy prevents ventilator-associated pneumonia in premature infants: a meta-analysis and systematic review

Keywords

nursing, premature infants, care, ventilator-associated pneumonia, Oral immunotherapy

Abstract

Introduction

Ventilator-associated pneumonia (VAP) prevention and care is essential to the prognosis of premature infants. We aimed to evaluate the effects and safety of oral immune therapy (OIT) in premature infants, to provide evidence for the clinical treatment and nursing care of premature infants.

Material and methods

We systematically searched PubMed, Embase, Cochrane Library, Web of Science, Cumulative Index of Nursing and Allied Health Literature (CINAHL), China National Knowledge Infrastructure (CNKI), China Biomedical Documentation Service (CBM), Wanfang databases for randomized controlled trials (RCTs) on the effects and safety of OIT in preterm infants until July 16, 2022. Two researchers independently screened the literature and extracted data. Revman 5.3 software was used for data meta-analysis.

Results

10 RCTs involving 852 premature infants were included, 427 premature infants received OIT. Synthesized outcomes showed that OIT reduced the incidence of VAP [RR=0.34, 95%CI (0.22-0.53)], the detection rate of tracheal tube-causing microorganisms [RR=0.29, 95%CI (0.16-0.50)] and length of hospital stay [MD=-6.60, 95%CI (-11.66, -1.53)] in premature infants (all $P<0.05$). There were no statistically differences in the detection rate of oropharyngeal pathogenic microorganisms [RR=0.23, 95%CI (0.04-1.32)], duration of mechanical ventilation [MD=-0.67, 95%CI (-1.37, 0.03)], mortality [RR=0.60, 95%CI (0.31, 1.14)] between OIT and control group (all $P>0.05$).

Conclusions

OIT is a simple and effective nursing method, which provides a new approach for the prevention of VAP in premature infants. RCTs with high quality, larger sample size and multi-centers are still needed for further verification on the role of OIT in the future.

1 **Title page**

2 Title: Oral immunotherapy prevents ventilator-associated pneumonia in premature infants: a meta-
3 analysis and systematic review

4 Running title: Oral immunotherapy & premature infants

5 Authors: Yue Yao*¹, Cheng Tan*², Lijiao He*², Yinsuo Ji¹, Hui Rong¹, Fei Yu#²

6 ¹, NICU, Children's Hospital of Nanjing Medical University, Nanjing, China

7 ², Department of laboratory, Children's Hospital of Nanjing Medical University, Nanjing, China

8 #, Corresponding author

9 Corresponding to: Fei Yu iibt93mjd4n@126.com

10 Address: No. 72, Guangzhou Road, Hunan Road Street, Gulou District, Nanjing, Jiangsu Province,
11 China.

12 Telephone: 13620561826

13 Fax: 0211 0921 5199

14

15 **Oral immunotherapy prevents ventilator-associated pneumonia in premature infants: a**
16 **meta-analysis and systematic review**

17 **Abstract**

18 Introduction: Ventilator-associated pneumonia (VAP) prevention and care is essential to the
19 prognosis of premature infants. We aimed to evaluate the effects and safety of oral immune
20 therapy (OIT) in premature infants, to provide evidence for the clinical treatment and nursing care
21 of premature infants.

22 Methods: We systematically searched PubMed, Embase, Cochrane Library, Web of Science,
23 Cumulative Index of Nursing and Allied Health Literature (CINAHL), China National Knowledge
24 Infrastructure (CNKI), China Biomedical Documentation Service (CBM), Wanfang databases for
25 randomized controlled trials (RCTs) on the effects and safety of OIT in preterm infants until July
26 16, 2022. Two researchers independently screened the literature and extracted data. Revman 5.3
27 software was used for data meta-analysis.

28 Results: 10 RCTs involving 852 premature infants were included, 427 premature infants received
29 OIT. Synthesized outcomes showed that OIT reduced the incidence of VAP [RR=0.34, 95%CI
30 (0.22-0.53)], the detection rate of tracheal tube-causing microorganisms [RR=0.29, 95%CI (0.16-
31 0.50)] and length of hospital stay [MD=-6.60, 95%CI (-11.66, -1.53)] in premature infants (all
32 P<0.05). There were no statistically differences in the detection rate of oropharyngeal pathogenic
33 microorganisms [RR=0.23, 95%CI (0.04-1.32)], duration of mechanical ventilation [MD=-0.67,
34 95%CI (-1.37, 0.03)], mortality [RR=0.60, 95%CI (0.31, 1.14)] between OIT and control group
35 (all P>0.05).

36 Conclusions: OIT is a simple and effective nursing method, which provides a new approach for

37 the prevention of VAP in premature infants. RCTs with high quality, larger sample size and multi-
38 centers are still **needed for** further verification on **the** role of OIT in the future.

39 **Keywords:** Oral immunotherapy; ventilator-associated pneumonia; premature infants; nursing;
40 care.

41

42 **Introduction**

43 Ventilator-associated pneumonia (VAP) is the pneumonia **that occurs** in patients with endotracheal
44 intubation or tracheotomy within 48 hours of receiving **mechanical ventilation (MV)** or within 48
45 hours of weaning and extubation[1]. Neonatal intensive care unit (NICU) is one of the common
46 sites of nosocomial infections. According to statistics, the incidence of VAP in NICU **can be as**
47 **high as** 45.11%, and the case fatality rate is as high as 19.04%[2-4]. VAP **increase** the NICU stay
48 and length of hospital stay of MV premature infants, increase the cost of treatment and the
49 economic burden of infants 's families[5, 6]. Therefore, the prevention and care of VAP is **of great**
50 **significance to** the prognosis of premature infants.

51 Due to the low level of oral self-cleaning ability and the thin and tender oral mucosa, premature
52 infants **are vulnerable to** injury and local infection[7]. Previous studies[8, 9] have reported that
53 effective oral care can prevent bacterial colonization of the upper respiratory tract and reduce the
54 occurrence of VAP. Oral immune therapy (OIT) is also known as colostrum oral instillation or
55 smear, **that is**, a very small amount of colostrum (usually 0.2 ml) is applied to the oral mucosa
56 **with** a sterile cotton swab or oral applicator[10]. Colostrum is rich in a variety of immune
57 substances, such as sIgA, lactoferrin, lysozyme and complement, etc. **Instilling or smearing**
58 **colostrum** on the oral and buccal mucosa of premature infants may improve the immunity of

59 premature infants. In MV infants, the establishment of artificial airway cannot realize the
60 absorption of colostrum through the lymphoid tissue or oral mucosa of the oropharynx and exert
61 an immune function, which loses the protective effect of colostrum to a certain extent[11, 12]. At
62 present, many studies[13-15] have reported that the use of colostrum can enhance the immunity of
63 newborns, prevent pathogenic bacteria from colonizing the respiratory tract and digestive tract
64 mucosa, thereby protecting the mucosal immune barrier, but the sample size of the study is small
65 and there are some different findings. Therefore, we conducted a meta-analysis to systematically
66 evaluate the preventive effect of OIT on VAP in premature infants, aiming to provide evidence
67 support for clinical VAP prevention and nursing care of premature infants.

68 **Methods**

69 This meta-analysis and systematic review was performed according to the statement of preferred
70 reporting items for systematic reviews and meta-analyses (PRISMA)[16].

71 Literature search strategy

72 We systematically searched PubMed, Embase, Cochrane Library, Web of Science, Cumulative
73 Index of Nursing and Allied Health Literature (CINAHL), China National Knowledge
74 Infrastructure (CNKI), China Biomedical Documentation Service (CBM), Wanfang and VIP
75 databases for randomized controlled trials (RCTs) on the effects and safety of OIT in premature
76 infants. The database retrieval time was from the inception of database to July 16, 2022. The
77 search formula used in the database search was ("infant" OR "newborn" OR "preterm" OR
78 "premature" OR "low birth weight") AND ("milk" OR "breast milk" OR "mother's milk" OR
79 "colostrum") AND ("oral care" OR "mouth care" OR "oral administration" OR "oropharyngeal
80 administration" OR "oral immune therapy"). The database searches were conducted using the

81 combination of subject headings and keywords. In addition, we used a 'snowball' approach to trace
82 relevant references of relevant RCTs and important reviews.

83 Literature Inclusion and Exclusion Criteria

84 The inclusion criteria for this meta-analysis were: (1) Study design: RCTs on the OIT in premature
85 infants. (2) Research population: Premature infants who met the diagnostic criteria for premature
86 infants and were admitted to the NICU 24 hours after birth, with no oral mucosal damage and
87 infection. (3) Intervention measures: the control group received routine oral care or 0.9% sodium
88 chloride solution or sterile water for oral care, and the intervention group received OIT. (4) The
89 article reported the relevant outcome indicators, including the incidence of VAP, the duration of
90 MV, the detection rate of oropharyngeal pathogenic microorganisms, the detection rate of
91 pathogenic microorganisms in endotracheal tube, the length of hospital stay and mortality. The
92 exclusion criteria for this meta-analysis were: (1) duplicate published literature; (2) literature for
93 which full text or related data could not be obtained by various methods.

94 Literature screening and data extraction

95 Two researchers independently screened the literature and extracted data strictly according to the
96 inclusion and exclusion criteria, and they cross-checked the obtained results. In case of
97 disagreement, consensus was reached after discussion or a third party was consulted. The content
98 extracted in this meta-analysis included the first author of the study, publication year, country,
99 sample size, intervention measures, and outcome indicators.

100 Literature quality evaluation

101 Two researchers independently evaluated the quality of the included RCTs according to the
102 evaluation criteria recommended by the Cochrane library, and consulted a third party if they

103 disagreed. This quality assessment method includes randomization methods, allocation
104 concealment, blinding of interventionists and participants, blinding of outcome assessors,
105 completeness of outcome data, selective reporting, and other biases. Every item can be rated as
106 “low”, “unclear”, or “high” risk of biases.

107 Statistical methods

108 We used Revman 5.3 software to perform meta-analysis on the data. For continuous variables we
109 used mean difference (MD) as the effect index, and for dichotomous variables we used relative
110 risk (RR) as the effect index. All analyses used 95% confidence intervals (CIs) as effect sizes. The
111 statistical heterogeneity of the studies was tested by the chi-square test. If $P > 0.1$ and $I^2 < 50\%$, a
112 fixed-effect model was selected for meta-analysis; otherwise, a random-effect model was applied.
113 Publication bias was assessed with funnel plots, and the asymmetry was evaluated by conducting
114 Egger regression test. Besides, we performed sensitivity analyses to evaluate the impact of single
115 study on the synthesized results. In this meta-analysis, $P < 0.05$ was considered as a statistically
116 significant difference between the groups

117 Results

118 Literature search results

119 227 related literatures were initially detected. After removing duplicate literatures, 216 articles
120 remained. After reading the title, abstract, 170 articles that did not meet the inclusion criteria were
121 excluded. The full text was searched and the remaining 46 articles were read through, and 36
122 articles were further excluded. Finally, 10 RCTs[17-26] were included for meta-analysis. The
123 literature screening process is shown in Figure 1.

124

125 Figure 1 The PRISMA flow diagram of RCT selection

126 Characteristics of included studies

127 Of the 10 RCTs[17-26] included, a total of 852 premature infants were involved, of which 427
128 premature infants received OIT and 425 were in the control group. The included studies were from
129 China, Egypt, South Korea, the United States and India. The basic characteristics of the included
130 studies are shown in Table 1.

131 Table 1 The characteristics of included RCTs

132

133 Quality evaluation of included RCTs

134 The risk of bias for included RCTs are showed in Figures 2 and 3. All included RCTs mentioned
135 randomization in their reports, but two RCTs did not report the detailed methods used to generate
136 random sequence. Four RCTs reported the methods to perform allocation concealment. The
137 performance bias and blinding design in the outcome assessment remained unclear. No other
138 biases were found amongst the included RCTs.

139

140 Figure 2 Risk of bias graph

141

142 Figure 3 Risk of bias summary

143

144 Meta-analysis

145 ● *The incidence of VAP* A total of 9 RCTs reported the effect of OIT on the incidence of VAP in
146 premature infants. There was no significant statistical heterogeneity among the studies

147 ($I^2=0\%$, $P=0.48$), so the fixed effect model was used for statistical analysis. The results
148 showed that the incidence of VAP in the OIT group was less than that in the control group,
149 and the difference was statistically significant [RR=0.34, 95%CI (0.22-0.53), $P<0.001$,
150 Figure 4A].

151 ● *The detection rate of pathogenic microorganisms in the tracheal tube* A total of 4 RCTs
152 reported the effect of OIT on the detection rate of pathogenic microorganisms in the tracheal
153 tube in premature infants. There was no significant statistical heterogeneity among the
154 studies ($I^2=0\%$, $P=0.42$), so the fixed effect model was used for statistical analysis. The
155 results showed that the detection rate of pathogenic microorganisms in the tracheal tube in
156 the OIT group was less than that in the control group, and the difference was statistically
157 significant [RR=0.29, 95%CI (0.16-0.50), $P<0.001$, Figure 4B].

158 ● *The detection rate of oropharyngeal pathogenic microorganisms* A total of 4 RCTs reported
159 the effect of OIT on the detection rate of oropharyngeal pathogenic microorganisms in
160 premature infants. There was significant statistical heterogeneity among the studies ($I^2=68\%$,
161 $P=0.04$), so the random effect model was used for statistical analysis. The results showed that
162 there was no statistically difference in the detection rate of oropharyngeal pathogenic
163 microorganisms between OIT and control group [RR=0.23, 95%CI (0.04-1.32), $P=0.10$,
164 Figure 4C].

165

166 Figure 4 The forest plots for synthesized outcomes

167 ● *The duration of MV* A total of 6 RCTs reported the effect of OIT on the duration of MV in
168 premature infants. There was significant statistical heterogeneity among the studies ($I^2=92\%$,

169 P<0.001), so the random effect model was used for statistical analysis. The results showed
170 that there was no statistically difference in the duration of MV between OIT and control
171 group [MD=-0.67, 95%CI (-1.37, 0.03), P=0.06, Figure 5A].

172 ● *The length of hospital stay* A total of 7 RCTs reported the effect of OIT on the length of
173 hospital stay in premature infants. There was significant statistical heterogeneity among the
174 studies ($I^2=98%$, $P<0.001$), so the random effect model was used for statistical analysis. The
175 results showed that the length of hospital stay in the tracheal tube in the OIT group was less
176 than that in the control group, and the difference was statistically significant [MD=-6.60,
177 95%CI (-11.66, -1.53), $P=0.01$, Figure 5B].

178 ● *Mortality* A total of 6 RCTs reported the effect of OIT on the mortality in premature infants.
179 There was no significant statistical heterogeneity among the studies ($I^2=0%$, $P=0.84$), so the
180 fixed effect model was used for statistical analysis. The results showed that there was no
181 statistically difference in the mortality between OIT and control group [RR=0.60, 95%CI
182 (0.31, 1.14), $P=0.12$, Figure 5C].

183

184 Figure 5 The forest plots for synthesized outcomes

185 Publication bias and sensitivity analysis

186 The funnel plots on the risk of publication bias are presented in Figure 6, and the results of Egger
187 test showed that there was no publication bias amongst the synthesized outcomes (all $P > 0.05$). We
188 excluded every RCT on each result one by one to check that if the overall results were changed,
189 and we found that the overall results **were not** altered by **removing** any one of included RCTs.

190

Figure 6 The funnel plots for synthesized outcomes

191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212

Discussions

VAP is one of the main complications of invasive MV and a common type of nosocomial infection, which seriously affects the prognosis of neonates[27, 28]. Relevant studies[29, 30] have found that oral colonization flora is an important source of pathogenic bacteria that cause VAP. The oral mucosa of premature infants is thin and tender with abundant blood vessels, the salivary glands are not fully developed and secreted less than adults, the oral mucosa is dry and vulnerable to injury and local infection[31]. The establishment of artificial airways makes it impossible for infants to breastfeed orally. It destroys the natural barrier function of the oral and nasal cavity of children to bacteria, so effective oral intervention for MV infants is of great significance to prevent the occurrence of VAP[32, 33]. The results of this present meta-analysis have found that compared with routine oral care in premature infants, OIT is beneficial to reduce the incidence of VAP, the detection rate of tracheal tube-causing microorganisms and length of hospital stay in premature infants, which is worthy of clinical application.

Colostrum is rich in cytokines and immune agents, which can provide antibacterial, bactericidal, antiviral, anti-inflammatory, immune regulation and anti-infection protection[34]. Colostrum oral smear can be used as a nutritional feeding supplement and potential immunotherapy. Rodriguez et al.[35] described oral smearing of colostrum in premature infants from a theoretical perspective, showing that colostrum can provide the greatest range of protection for very low birth weight (VLBW) infants. In previous studies[36-38], the safety and feasibility of applying colostrum to the oral cavity are preliminarily explored. The vital signs of the children before and after OIT operation are stable, and no adverse reactions occur. Moreover, the time for children in the OIT

213 group to reach complete enteral feeding is significantly earlier, **indicating that** the use of colostrum
214 smearing in the oral cavity is simple and easy, and **it** can be well tolerated by ultra-low birth
215 weight infants in critical condition. OIT is economical and good safety, and it may bring positive
216 clinical significance.

217 In a previous study[39], VLBW infants were randomly divided into a colostrum group and a
218 normal saline solution control group. The intervention started within 48 hours after birth, and the
219 oral smear was performed every 2 hours for 48 hours, quantitative detection was performed 6
220 hours after the intervention. The content of sIgA, lactoferrin and other immune substances in urine
221 and saliva increased after oral application of colostrum, **indicating that** the abundant immune
222 factors in colostrum and the stimulation of oropharyngeal lymphoid tissue through the
223 oropharyngeal pathway strengthens the immune system of immature neonates and it can provide
224 early immune protection for premature infants. In addition, a study [40] retrospectively analyzed
225 infants with a body weight of $\leq 1500\text{g}$ in a hospital's NICU who were using MV. After oral
226 smearing of colostrum for these infants, the number of days on the machine and the number of
227 days in hospital were not statistically significant between the two groups. But the positive rate
228 indicators of tracheal secretion culture and blood culture decreased after the intervention. At the
229 same time, some studies[41, 42] have shown that the intervention of oral smearing of colostrum in
230 VLBW infants can last for 48 hours to affect the colonization of oral microorganisms, **which**
231 **provides a basis for** OIT to prevent VAP in premature infants.

232 The dosage of colostrum smear in OIT is relatively uniform in various literatures, **all of which** are
233 0.2 mL/time, 0.1 mL on each side, and the dosage is small for precise control. During the OIT, it is
234 recommended to accurately apply colostrum to both sides of the oral mucosa of the infants, pay

235 attention to gentle movements, maintain the integrity of the oral mucosa, and prevent the cotton
236 swab or cotton ball from falling off and causing choking or suffocation in the infant's mouth[43].
237 The starting time is generally 48 to 96 hours after birth, and the frequency is smeared every 2 to 3
238 hours or 3 to 4 hours for 48 hours or until the child can be fed orally[44]. **It must be noted that**
239 **most NICUs in China are mother-infant separation wards, and visitors are not allowed during**
240 **hospitalization[45].** Fresh colostrum or refrigerated colostrum is required for each oral application,
241 and family members are required to actively cooperate with daily delivery of fresh breast milk to
242 the hospital. **Therefore, the importance of oral smearing of colostrum should be informed to the**
243 **family members of the children through various forms of education, and the collection, storage**
244 **and transportation of colostrum should be explained in detail, and the family members should be**
245 **involved in the work of caring for the infants[46, 47].** Active help and nursing care from health
246 care providers can increase family members' confidence in treatment and relieve the mother's guilt
247 and anxiety that she cannot directly care for the child. For the storage of colostrum, freezing **will**
248 **destroy the protein molecular structure in colostrum and inactivate the active substances in**
249 **colostrum[48, 49]. Therefore, fresh colostrum or refrigerated colostrum should be used for OIT to**
250 **ensure the safety and effect of OIT[50, 51].**

251 There are some limitations of this meta-analysis that deserve careful consideration. **Firstly,** the
252 RCTs included in this meta-analysis generally have problems of allocation concealment and
253 insufficient blinding, resulting in the possibility of bias to varying degrees. **Secondly,** there are
254 relatively few studies on the prevention of VAP in premature infants by OIT, and the sample size
255 of the studies is relatively small, the long-term impact of OIT on premature infants remains to be
256 explored. **Thirdly,** most of the included research reports were from a few countries such as China,

257 and there may be some population and regional differences in the research results. **The effect and**
258 **safety of OIT still need to be further explored in follow-up studies with large samples and multiple**
259 **regions.**

260 **Conclusions**

261 In conclusion, the results of this meta-analysis show that OIT can prevent VAP in premature
262 infants, **reduce** the detection rate of pathogenic microorganisms in the tracheal tube, and shorten
263 the length of hospital stay. **It is recommended that follow-up studies adopt a more rigorous design,**
264 **and clarify the gestational age, birth weight, frequency of intervention, frequency of intervention,**
265 **etc. More large-sample, multi-center, high-quality RCT should be carried out to further evaluate**
266 **the effect of OIT on the duration of MV, the detection rate of pathogenic microorganisms in the**
267 **oropharynx, and the mortality of premature infants.** Besides, the direct immune effect of OIT
268 should be quantified to assess the effect of oral smearing of colostrum on the oral flora of
269 premature infants, to provide more insights to **the** clinical treatment and care of premature infants.

270 **Declarations**

271 **Ethics approval and consent to participate**

272 In this study, all methods were performed in accordance with the relevant guidelines and
273 regulations. Ethics approval and consent to participate are not necessary since our study is a meta-
274 analysis.

275 **Consent for publication**

276 Not applicable.

277 **Availability of data and materials**

278 All data generated or analyzed during this study are included in this published article.

279 **Competing interests**

280 The authors declare that they have no competing interests.

281 **Funding**

282 None.

283 **Author contributions**

284 Y Y, C T, F Y designed research; Y Y, C T, L H, Y J, H R, F Y conducted research; Y Y, C T, L H
285 analyzed data; Y Y, F Y wrote the first draft of manuscript; Y Y had primary responsibility for
286 final content. All authors read and approved the final manuscript.

287 **Acknowledgments**

288 None.

289 **List of abbreviations**

290 VAP: ventilator-associated pneumonia

291 NICU: neonatal intensive care unit

292 OIT: oral immune therapy

293 CINAHL: Cumulative Index of Nursing and Allied Health Literature

294 CNKI: China National Knowledge Infrastructure

295 CBM: China Biomedical Documentation Service

296 RCTs: randomized controlled trials

297 PRISMA: preferred reporting items for systematic reviews and meta-analyses

298 MD: mean difference

299 RR: relative risk

300 CI: confidence interval

301 **References**

- 302 1. Ranzani OT, Niederman MS, Torres A: **Ventilator-associated pneumonia.**
303 *Intensive Care Med* 2022.
- 304 2. Ergenekon E, Cataltepe S: **Ventilator-associated pneumonia in the NICU: time**
305 **to boost diagnostics?** *Pediatr Res* 2020, **87(7):1143-1144.**
- 306 3. Niedzwiecka T, Patton D, Walsh S, Moore Z, O'Connor T, Nugent L: **What are**
307 **the effects of care bundles on the incidence of ventilator-associated**
308 **pneumonia in paediatric and neonatal intensive care units? A systematic**
309 **review.** *J Spec Pediatr Nurs* 2019, **24(4):e12264.**
- 310 4. Rangelova VR, Raycheva RD, Kevorkyan AK, Krasteva MB, Kalchev YI:
311 **Ventilator-Associated Pneumonia in Neonates Admitted to a Tertiary Care**
312 **NICU in Bulgaria.** *Front Pediatr* 2022, **10:909217.**
- 313 5. Alriyami A, Kiger JR, Hooven TA: **Ventilator-Associated Pneumonia in the**
314 **Neonatal Intensive Care Unit.** *Neoreviews* 2022, **23(7):e448-e461.**
- 315 6. Teng G, Wang N, Nie X, Zhang L, Liu H: **Analysis of risk factors for early-**
316 **onset ventilator-associated pneumonia in a neurosurgical intensive care**
317 **unit.** *BMC Infect Dis* 2022, **22(1):66.**
- 318 7. Verhasselt V: **Is infant immunization by breastfeeding possible?** *Philos*
319 *Trans R Soc Lond B Biol Sci* 2015, **370(1671).**
- 320 8. Qi W, Xianhong Z: **Research progress of oral smearing of colostrum on the**
321 **prevention of ventilator-associated pneumonia in premature infants.** *Journal*
322 *of Nursing* 2017, **24(24):4-6.**
- 323 9. Qingsi T, Xiaoxia C, Xing C: **The application effect of meticulous oral care**
324 **in the prevention of ventilator-associated pneumonia in premature infants.**
325 *Chinese Journal of Modern Nursing* 2015, **16(21):3-7.**
- 326 10. Nasuf AWA, Ojha S, Dorling J: **Oropharyngeal colostrum in preventing**
327 **mortality and morbidity in preterm infants.** *Cochrane Database Syst Rev* 2018,
328 **9:CD011921.**
- 329 11. Mohammed AR, Eid AR, Elzehery R, Al-Harrass M, Shouman B, Nasef N: **Effect**
330 **of Oropharyngeal Administration of Mother's Milk Prior to Gavage Feeding on**
331 **Gastrin, Motilin, Secretin, and Cholecystokinin Hormones in Preterm Infants:**
332 **A Pilot Crossover Study.** *JPEN J Parenter Enteral Nutr* 2021, **45(4):777-783.**
- 333 12. Huo M, Liu C, Mei H, Zhang Y, Liu C, Song D, Zhang Y, Zhang Y, Xin C:
334 **Intervention Effect of Oropharyngeal Administration of Colostrum in Preterm**
335 **Infants: A Meta-Analysis.** *Front Pediatr* 2022, **10:895375.**
- 336 13. Chen LL, Liu J, Mu XH, Zhang XY, Yang CZ, Xiong XY, Wang MQ: **Oropharyngeal**
337 **administration of mother's own milk influences levels of salivary sIgA in**
338 **preterm infants fed by gastric tube.** *Sci Rep* 2022, **12(1):2233.**
- 339 14. Xavier Ramos MS, Martins CDC, Souza ES, Vieira GO, Gomes-Filho IS,
340 Figueiredo A, Pereira MG, Cruz SSD: **Oropharyngeal colostrum immunotherapy**
341 **and nutrition in preterm newborns: meta-analysis.** *Rev Saude Publica* 2021,
342 **55:59.**
- 343 15. OuYang X, Yang CY, Xiu WL, Hu YH, Mei SS, Lin Q: **Oropharyngeal**

- 344 administration of colostrum for preventing necrotizing enterocolitis and
345 late-onset sepsis in preterm infants with gestational age \leq 32 weeks: a
346 pilot single-center randomized controlled trial. *Int Breastfeed J* 2021,
347 16(1):59.
- 348 16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting
349 items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*
350 2009, 339:b2535.
- 351 17. Abd-Elgawad M, Eldeglia H, Khashaba M, Nasef N: Oropharyngeal Administration
352 of Mother's Milk Prior to Gavage Feeding in Preterm Infants: A Pilot
353 Randomized Control Trial. *JPEN J Parenter Enteral Nutr* 2020, 44(1):92-104.
- 354 18. Fang S: The effect of oral immunotherapy on the prevention of ventilator-
355 associated pneumonia in premature infants. *Nursing Practice and Research*
356 2020, 17(4):125-126.
- 357 19. Lee J, Kim HS, Jung YH, Choi KY, Shin SH, Kim EK, Choi JH: Oropharyngeal
358 colostrum administration in extremely premature infants: an RCT. *Pediatrics*
359 2015, 135(2):e357-366.
- 360 20. Li H, Jing X, Enyi W: A clinical randomized controlled study of colostrum
361 oral immunization in the prevention of ventilator-associated pneumonia in
362 premature infants. *Chongqing Medicine* 2020, 49(16):2751-2754.
- 363 21. Peiling H, Wenjuan Z, Liqian O: Analysis of the effect of oral application
364 of colostrum on body weight and oral feeding of premature infants. *Medical*
365 *Theory and Practice* 2022, 35(9):2-4.
- 366 22. Qianqian Z: The effect of colostrum oral immunotherapy in preventing
367 ventilator-associated pneumonia in premature infants *Clinical Practical*
368 *Integrative Medicine* 2021, 21(15): 81-82.
- 369 23. Shan D: Effects of oral infusion of colostrum on very low birth weight
370 infants under mechanical ventilation Qingdao: Qingdao University; 2018.
- 371 24. Sharma D, Kaur A, Farahbakhsh N, Agarwal S: Role of Oropharyngeal
372 Administration of Colostrum in Very Low Birth Weight Infants for Reducing
373 Necrotizing Enterocolitis: A Randomized Controlled Trial. *Am J Perinatol*
374 2020, 37(7):716-721.
- 375 25. Sohn K, Kalanetra KM, Mills DA, Underwood MA: Buccal administration of
376 human colostrum: impact on the oral microbiota of premature infants. *J*
377 *Perinatol* 2016, 36(2):106-111.
- 378 26. Yumei L, Yingjie P, Yingying C: Effect of early oral instillation of
379 colostrum on mechanical ventilation in ultra-low birth weight premature
380 infants. *Chinese Journal of Nursing* 2020, 55(6):884-888.
- 381 27. Raycheva R, Rangelova V, Kevorkyan A: Cost Analysis for Patients with
382 Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit.
383 *Healthcare (Basel)* 2022, 10(6).
- 384 28. Arthur N, Kaur I, Carey AJ: Evaluation of the applicability of the current
385 CDC pediatric ventilator-associated events (PedVAE) surveillance definition
386 in the neonatal intensive care unit population. *BMC Pediatr* 2022, 22(1):185.
- 387 29. Beker F, Liley HG, Hughes IP, Jacobs SE, Macey J, Twitchell E, Davis PG:

- 388 **Effects on Growth of Smell and Taste of Milk During Tube Feeding of Preterm**
389 **Infants: A Randomized Clinical Trial.** *JAMA Pediatr* 2021, **175**(11):1115-1123.
- 390 30. da Cruz Martins C, de Santana Xavier Ramos M, Viana Cardoso Amaral M,
391 Santos Passos Costa J, Souza Cerqueira E, de Oliveira Vieira T, d ACSS,
392 Oliveira Vieira G: **Colostrum oropharyngeal immunotherapy for very low birth**
393 **weight preterm infants: protocol of an intervention study.** *BMC Pediatr* 2020,
394 **20**(1):371.
- 395 31. Ma A, Yang J, Li Y, Zhang X, Kang Y: **Oropharyngeal colostrum therapy**
396 **reduces the incidence of ventilator-associated pneumonia in very low birth**
397 **weight infants: a systematic review and meta-analysis.** *Pediatr Res* 2021,
398 **89**(1):54-62.
- 399 32. Evidence-Based Medicine Group NSCMDA: **[Clinical guidelines for the**
400 **diagnosis and treatment of feeding intolerance in preterm infants (2020)].**
401 *Zhongguo Dang Dai Er Ke Za Zhi* 2020, **22**(10):1047-1055.
- 402 33. Jing Z, Yingying C, Xuehong C: **The application effect of breast milk oral**
403 **smear in the prevention of ventilator-associated pneumonia in very low**
404 **birth weight infants.** *Chinese Journal of Medicine and Clinical Medicine*
405 2019, **19**(3):3-7.
- 406 34. Huiwen C, Yuelan M, Yongshu L: **Meta-analysis of oral immunotherapy on the**
407 **prevention of ventilator-associated pneumonia in premature infants.** *Chinese*
408 *Journal of Modern Nursing* 2021, **27**(19):7-11.
- 409 35. Rodriguez NA, Meier PP, Groer MW, Zeller JM: **Oropharyngeal administration**
410 **of colostrum to extremely low birth weight infants: theoretical**
411 **perspectives.** *J Perinatol* 2009, **29**(1):1-7.
- 412 36. Rodriguez NA, Meier PP, Groer MW, Zeller JM, Engstrom JL, Fogg L: **A pilot**
413 **study to determine the safety and feasibility of oropharyngeal**
414 **administration of own mother's colostrum to extremely low-birth-weight**
415 **infants.** *Adv Neonatal Care* 2010, **10**(4):206-212.
- 416 37. Seigel JK, Smith PB, Ashley PL, Cotten CM, Herbert CC, King BA, Maynor AR,
417 Neill S, Wynn J, Bidegain M: **Early administration of oropharyngeal**
418 **colostrum to extremely low birth weight infants.** *Breastfeed Med* 2013,
419 **8**(6):491-495.
- 420 38. Garofalo NA, Caplan MS: **Oropharyngeal Mother's Milk: State of the Science**
421 **and Influence on Necrotizing Enterocolitis.** *Clin Perinatol* 2019, **46**(1):77-
422 88.
- 423 39. Ying Y, Qin Z, Shanyu J: **Clinical significance of oral immunotherapy of**
424 **colostrum in reducing the incidence of nosocomial infection in very low**
425 **birth weight premature infants.** *Chinese Journal of Clinical Medicine for*
426 *Women and Children* 2019, **15**(5):6-9.
- 427 40. Qingsi T, Xiaoxia C, Xing C: **The application effect of meticulous oral care**
428 **in the prevention of ventilator-associated pneumonia in premature infants.**
429 *Chinese Journal of Modern Nursing* 2015, **22**(21):3-5.
- 430 41. Lianhong W: **Analysis of the clinical effect of cluster nursing in the**
431 **prevention of ventilator-associated pneumonia in premature infants.**

- 432 *Heilongjiang Medicine* 2017, **30**(3):2-6.
- 433 42. Lianhong W, Ying L, Yanjin L: **Effect of improved cluster nursing strategy**
434 **in the prevention of ventilator-associated pneumonia in very low birth**
435 **weight premature infants.** *Nursing Practice and Research* 2018, **15**(7):3-5.
- 436 43. Meifang W, Xiumei D, Shixia D: **Efficacy of colostrum oral immunotherapy (C-**
437 **OIT) in premature infants.** *Journal of General Stomatology* 2016, **3**(7): 3-6.
- 438 44. Xiping Z, Meiqin X: **Research progress of colostrum oral immunotherapy in**
439 **super/very low birth weight premature infants.** *Chinese Journal of*
440 *Neonatology* 2018, **33**(1):3-6.
- 441 45. Fang L, Tingting C, Qing T: **Application of NICU detail management model in**
442 **nursing risk prevention** *Qilu Nursing Journal* 2021, **27**(5):3-5.
- 443 46. Sanchez Luna M, Martin SC, Gomez-de-Orgaz CS: **Human milk bank and**
444 **personalized nutrition in the NICU: a narrative review.** *Eur J Pediatr* 2021,
445 **180**(5):1327-1333.
- 446 47. Martin-Alvarez E, Diaz-Castro J, Pena-Caballero M, Serrano-Lopez L, Moreno-
447 Fernandez J, Sanchez-Martinez B, Martin-Peregrina F, Alonso-Moya M,
448 Maldonado-Lozano J, Hurtado-Suazo JA *et al*: **Oropharyngeal Colostrum**
449 **Positively Modulates the Inflammatory Response in Preterm Neonates.**
450 *Nutrients* 2020, **12**(2).
- 451 48. Panchal H, Athalye-Jape G, Patole S: **Oropharyngeal Colostrum for Preterm**
452 **Infants: A Systematic Review and Meta-Analysis.** *Adv Nutr* 2019, **10**(6):1152-
453 1162.
- 454 49. Meier PP, Engstrom JL, Patel AL, Jegier BJ, Bruns NE: **Improving the use of**
455 **human milk during and after the NICU stay.** *Clin Perinatol* 2010, **37**(1):217-
456 245.
- 457 50. Huihui L: **Nursing progress of oral nursing in the prevention of ventilator-**
458 **associated pneumonia.** *Journal of Nursing Education* 2012, **27**(23):2124-2126.
- 459 51. Suhuan X, Qiaomei Z, Xin D: **Meta-analysis of the intervention effect of**
460 **oral immunotherapy on premature infants** *China Nursing Management* 2018,
461 **18**(10):1340-1346.

462

463

464 **Figure legends**

465 Figure 1 The PRISMA flow diagram of RCT selection

466 Figure 2 Risk of bias graph

467 Figure 3 Risk of bias summary

468 Figure 4 The forest plots for synthesized outcomes

469 Figure 5 The forest plots for synthesized outcomes

470 Figure 6 The funnel plots for synthesized outcomes

471

Preprint

Table 1 The characteristics of included RCTs

RCT	Country	Sample size		Gestational age (weeks)		Birth weight (g)		Interventions		OIT frequency	OIT duration
		OIT group	Control group	OIT group	Control group	OIT group	Control group	OIT group	Control group		
Abd 2019	Egypt	100	100	8.90±2.05	28.80±2.26	1050±246	1022±249	Colostrum oropharyngeal instillation 0.2 ml/time	Routine care	q 2~4 h	NA
Du 2018	China	45	45	30.50±1.30	30.70±1.20	1281±205	1221±191	Colostrum oropharyngeal 1 0.2 ml/time	0.9% sodium chloride solution 0.2 ml/time	q 3h	7d
He 2020	China	28	29	30.73±1.84	30.77±2.00	1551.07±438.61	1611.03±552.12	Colostrum oropharyngeal 1 0.2 ml/time	0.9% sodium chloride solution 0.2 ml/time	q 4h	NA
Hu 2022	China	43	43	33.92 ± 1.66	33.86 ± 1.81	1670 ±350	1650±380	Colostrum oropharyngeal 1 0.2 ml/time	0.9% sodium chloride solution	q 4h	5~7d
Lee	Korea	22	21	26 (24,	26 (24,	815(610, 1003)	830(701, 993)	Colostrum	sterile	q 3h	7d

2015				27)	27)			oropharyngea 1 0.2 ml/time	water 0.2 ml/time		
Li 2020	China	51	53	27.01±0.9 8	26.59±1.2 1	775.01±223.18	809.01±180.18	Colostrum oropharyngea 1 0.2 ml/time	0.9% sodium chloride solution	q 4h	5d
Sharma 2020	India	59	58	29.10±1.8 0	29.20±1.9 0	1146±58	1158±61	Colostrum oropharyngea 1 instillation	Routine care	q 2h	72 h
Sohn 2016	USA	6	6	27(25, 30)	27(25, 28)	1092(490, 1 350)	1015(735, 1 300)	Colostrum oropharyngea 1 instillation 0.2 ml/time	Routine care	q 2h	46 h
Song 2020	China	40	40	34.61±1.4 4	34.22±1.5 6	2068±470	2069±450	Colostrum oropharyngea 1 0.2 ml/time	0.9% sodium chloride solution	q 3h	72 h
Zan 2021	China	33	30	NA	NA	2940±870	2670±750	Colostrum oropharyngea 1 0.2 ml/time	2% Sodium Bicarbonate oral care	q 3~4h	NA




Figure 1 The PRISMA flow diagram of RCT selection





Figure 2 Risk of bias graph

Preprint

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abd 2019	+	?	?	?	+	+	+
Du 2018	+	+	?	?	+	+	+
He 2020	?	?	?	?	+	+	+
Hu 2022	+	+	?	?	+	+	+
Lee 2015	+	?	?	?	+	+	+
Li 2020	+	+	?	?	+	+	+
Sharma 2020	+	?	?	?	+	+	+
Sohn 2016	?	?	?	?	+	+	+
Song 2020	+	?	?	?	+	+	+
Zan 2021	+	+	?	?	+	+	+


Figure 3 Risk of bias summary



A Forest plot for the incidence of VAP




B Forest plot for the detection rate of pathogenic microorganisms in the tracheal tube




C Forest plot for the detection rate of oropharyngeal pathogenic microorganisms


Figure 4 The forest plots for synthesized outcomes



A Forest plot for the duration of mechanical ventilation



B Forest plot for the length of hospital stay



C Forest plot for mortality

Figure 5 The forest plots for synthesized outcomes




Figure 6 The funnel plots for synthesized outcomes